1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
  4. > Sleep Disorders – Pipeline Review, H1 2013

Sleep Disorders – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 59 pages

Sleep Disorders – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Sleep Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Sleep Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sleep Disorders. Sleep Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Sleep Disorders.
- A review of the Sleep Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Sleep Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Sleep Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Sleep Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Sleep Disorders - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Sleep Disorders Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Sleep Disorders 8
Sleep Disorders Therapeutics under Development by Companies 10
Sleep Disorders Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Discovery and Pre-Clinical Stage Products 16
Comparative Analysis 16
Sleep Disorders Therapeutics - Products under Development by Companies 17
Sleep Disorders Therapeutics - Products under Investigation by Universities/Institutes 18
Companies Involved in Sleep Disorders Therapeutics Development 19
GlaxoSmithKline plc 19
Cephalon, Inc. 20
NovaDel Pharma, Inc. 21
CoLucid Pharmaceuticals, Inc. 22
Ferrer Internacional S.A. 23
Vanda Pharmaceuticals Inc. 24
Sleep Disorders - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
SB-649868 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
tasimelteon - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
zolpidem tartrate - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
caffeine, citrated - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
COL-204 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
ABT-652 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
SKL-N05 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Conjugated Stigmine Program - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Drug Targeting GABA Alpha 4 Delta Receptor - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Aryl-Heteroaryl Derivatives - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
Hypocretin-1 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
Orexin Modulator Program - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
Sleep Disorders Therapeutics - Drug Profile Updates 45
Sleep Disorders Therapeutics - Discontinued Products 49
Sleep Disorders Therapeutics - Dormant Products 50
Sleep Disorders - Product Development Milestones 51
Featured News and Press Releases 51
Oct 15, 2012: Vanda Pharma's Tasimelteon Restores Daily Cortisol Rhythms In Blind Patients With Non-24-hour disorder 51
Aug 10, 2012: Mylan Launches Generic Provigil Tablets 52
Jul 23, 2012: Mitsubishi Tanabe Pharma Announces Launch Of Tranquilizer Depas Tablets 0.25Mg 52
Jun 11, 2012: Vanda Pharma Presents New Data Of Tasimelteon At SLEEP 2012 26th Annual Meeting Of Associated Professional Sleep Societies 52
May 22, 2012: Vanda Presents Clinical Data Of Tasimelteon At Annual Meeting Of Society For Research On Biological Rhythms 53
Jan 26, 2012: Initial Clinical Data Reveal Potential Of Vanda's Tasimelteon To Reset Body Clock In Non-24-Hour Sleep-Wake Disorder 53
Nov 25, 2011: Alfresa And Mitsubishi Tanabe Pharma Announce Approval Of Additional Indication For Modiodal Tablets 100mg 54
May 20, 2011: VIVUS Announces Multiple Presentations Featuring QNEXA Data To Be Presented At European Congress On Obesity 54
May 06, 2011: Cephalon Reports Positive Phase IV Trial Results With NUVIGIL In Largest Shift Work Disorder Trial 55
Jan 10, 2011: Shire Reports Positive Signal Finding Study Of Investigative Use Of Vyvanse Capsules CII In Excessive Daytime Sleepiness Model 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59



List of Tables

Number of Products Under Development for Sleep Disorders, H1 2013 8
Products under Development for Sleep Disorders - Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 11
Number of Products under Investigation by Universities/Institutes, H1 2013 12
Comparative Analysis by Late Stage Development, H1 2013 13
Comparative Analysis by Mid Clinical Stage Development, H1 2013 14
Comparative Analysis by Early Clinical Stage Development, H1 2013 15
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 16
Products under Development by Companies, H1 2013 17
Products under Investigation by Universities/Institutes, H1 2013 18
GlaxoSmithKline plc, H1 2013 19
Cephalon, Inc., H1 2013 20
NovaDel Pharma, Inc., H1 2013 21
CoLucid Pharmaceuticals, Inc., H1 2013 22
Ferrer Internacional S.A., H1 2013 23
Vanda Pharmaceuticals Inc., H1 2013 24
Assessment by Monotherapy Products, H1 2013 25
Assessment by Stage and Route of Administration, H1 2013 27
Assessment by Stage and Molecule Type, H1 2013 29
Sleep Disorders Therapeutics - Drug Profile Updates 45
Sleep Disorders Therapeutics - Discontinued Products 49
Sleep Disorders Therapeutics - Dormant Products 50



List of Figures

Number of Products under Development for Sleep Disorders, H1 2013 8
Products under Development for Sleep Disorders - Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Products under Investigation by Universities/Institutes, H1 2013 12
Late Stage Products, H1 2013 13
Mid Clinical Stage Products, H1 2013 14
Early Clinical Stage Products, H1 2013 15
Discovery and Pre-Clinical Stage Products, H1 2013 16
Assessment by Monotherapy Products, H1 2013 25
Assessment by Route of Administration, H1 2013 26
Assessment by Stage and Route of Administration, H1 2013 27
Assessment by Molecule Type, H1 2013 28
Assessment by Stage and Molecule Type, H1 2013 29

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Sleep Aids: Technologies and Global Markets

Sleep Aids: Technologies and Global Markets

  • $ 6650
  • Industry report
  • October 2016
  • by BCC Research

Use this report to: - Analyze the current market dynamics and evaluate the effect of strategic factors such as technology-driven change and industry consolidation of sleep aids and technologies. - Review ...

Sleeping Aids Market: By Sleep Disorder (Insomnia, Sleep Apnea, Restless Leg Syndrome, Narcolepsy, Sleep Walking) Product (Mattress & Pillow, Sleep Labs, Medication, Sleep Apena Devices) Medication (Prescription Based, OTC drugs, Herbal Drugs)-Forecast (2

Sleeping Aids Market: By Sleep Disorder (Insomnia, Sleep Apnea, Restless Leg Syndrome, Narcolepsy, Sleep Walking) Product (Mattress & Pillow, Sleep Labs, Medication, Sleep Apena Devices) Medication (Prescription Based, OTC drugs, Herbal Drugs)-Forecast (2

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Sleep aids are pills and medical devices that enable a person suffering from sleep disorder to fall asleep. Sleep aids consist of various products such as medications, sleep laboratories, sleep apnea devices, ...

Global Sleeping Aids Market Size, Share, Development, Growth and Demand Forecast to 2022 – Industry Insights by Sleep Disorder, by Products, by Products

Global Sleeping Aids Market Size, Share, Development, Growth and Demand Forecast to 2022 – Industry Insights by Sleep Disorder, by Products, by Products

  • $ 5100
  • Industry report
  • August 2016
  • by P&S Market Research

The global sleeping aids market accounted for $61,798.0 million in 2015, and it is expected to grow at a CAGR of 6.3% during 2016-2022. The Insomnia sleep disorder segment dominated the global sleeping ...

Consumer Health In The Us

September 2016 $ 2423

Consumer Health In Belgium

September 2016 $ 2423

Consumer Health In Austria

September 2016 $ 2423

Consumer Health In Canada

September 2016 $ 2423

Sleep Aids In Egypt

September 2016 $ 912

Download Unlimited Documents from Trusted Public Sources

Sleep Aid Markets in Pakistan

  • August 2016
    9 pages
  • Sleep Aid  

  • Pakistan  

View report >

OTC Markets in the US

  • July 2016
    2 pages
  • OTC  

    Marketing Resea...  

    Dietary Supplem...  

  • United States  

View report >

Sleep Aid Markets in the US

  • June 2016
    9 pages
  • Sleep Aid  

    Cancer  

    Therapy  

  • United States  

View report >

Otc Markets In The Us

9 months ago

Otc Industry In The Us

9 months ago

Therapy Market In The Us

11 months ago

Related Market Segments :

Sleep Aid

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.